Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.5%
|
$122,500
$49.93 P/Share
|
|
Dec 01
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
500
-0.38%
|
$24,500
$49.93 P/Share
|
|
Nov 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$60,000
$48.01 P/Share
|
|
Nov 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Nov 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.23%
|
$552,000
$46.47 P/Share
|
|
Nov 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.86%
|
$37,000
$2.67 P/Share
|
|
Nov 03
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$290,000
$58.54 P/Share
|
|
Nov 03
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
5,000
-9.45%
|
$75,000
$15.09 P/Share
|
|
Nov 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.44%
|
$150,000
$60.83 P/Share
|
|
Nov 01
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
500
-0.38%
|
$30,000
$60.83 P/Share
|
|
Oct 26
2022
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
130
-0.52%
|
$7,540
$58.41 P/Share
|
|
Oct 20
2022
|
James George Chopas VP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
130
-0.7%
|
$7,540
$58.0 P/Share
|
|
Oct 20
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
196
-0.67%
|
$11,368
$58.0 P/Share
|
|
Oct 14
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$73,750
$59.31 P/Share
|
|
Oct 14
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Oct 10
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.24%
|
$684,000
$57.5 P/Share
|
|
Oct 10
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.87%
|
$37,000
$2.67 P/Share
|
|
Oct 03
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.38%
|
$165,000
$66.69 P/Share
|
|
Oct 03
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$330,000
$66.69 P/Share
|
|
Oct 03
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.45%
|
$75,000
$15.09 P/Share
|
|
Sep 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$82,500
$66.0 P/Share
|
|
Sep 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Sep 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.25%
|
$756,000
$63.98 P/Share
|
|
Sep 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.89%
|
$37,000
$2.67 P/Share
|
|
Sep 08
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
15,000
-5.87%
|
$975,000
$65.0 P/Share
|
|
Sep 06
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$300,000
$60.38 P/Share
|
|
Sep 06
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.45%
|
$75,000
$15.09 P/Share
|
|
Sep 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.33%
|
$150,000
$60.3 P/Share
|
|
Aug 30
2022
|
James George Chopas VP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-2.92%
|
$32,364
$58.84 P/Share
|
|
Aug 25
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,306
+3.2%
|
$55,978
$13.19 P/Share
|
|
Aug 17
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$345,000
$69.5 P/Share
|
|
Aug 17
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Aug 16
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,394
+16.76%
|
$355,516
$14.0 P/Share
|
|
Aug 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$83,750
$67.21 P/Share
|
|
Aug 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Aug 15
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-22.56%
|
$862,500
$69.0 P/Share
|
|
Aug 15
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+18.41%
|
$187,500
$15.09 P/Share
|
|
Aug 11
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
30,000
-10.5%
|
$1,950,000
$65.63 P/Share
|
|
Aug 11
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$335,000
$67.0 P/Share
|
|
Aug 11
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Aug 11
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-22.56%
|
$837,500
$67.0 P/Share
|
|
Aug 11
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+18.41%
|
$187,500
$15.09 P/Share
|
|
Aug 08
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$320,000
$64.5 P/Share
|
|
Aug 08
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Aug 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.25%
|
$744,000
$62.5 P/Share
|
|
Aug 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.9%
|
$37,000
$2.67 P/Share
|
|
Aug 08
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-22.56%
|
$812,500
$65.0 P/Share
|
|
Aug 08
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+18.41%
|
$187,500
$15.09 P/Share
|
|
Aug 04
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
10,000
-13.67%
|
$600,000
$60.75 P/Share
|
|
Aug 04
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.3%
|
$150,000
$15.52 P/Share
|